倍氯米松作用机制 - Medchemexpress - MCE中国

1、Product Data SheetBeclometasoneCat. No.: HY-B1540CAS No.: 4419-39-0分式: CHClO分量: 408.92作靶点: Glucocorticoid Receptor作通路: GPCR/G Protein储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 32 mg/mL (78.25 mM)* means soluble, but saturation unknown.SolventMass1 mg 5 mg

2、10 mgConcentration制备储备液1 mM 2.4455 mL 12.2273 mL 24.4547 mL5 mM 0.4891 mL 2.4455 mL 4.8909 mL10 mM 0.2445 mL 1.2227 mL 2.4455 mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 储存时，请在 6 个内使，-20C 储存时，请在 1 个内使。体内实验请根据您的实验动物和给药式选择适当的溶解案。以下溶解案都请先按照 In V

3、itro 式配制澄清的储备液，再依次添加助溶剂：为保证实验结果的可靠性，澄 的储备液可以根据储存条件，适当保存；体内实验的作液，建议您现现配，当天使； 以下溶剂前显的百分 指该溶剂在您配制终溶液中的体积占；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的式助溶1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.25 mg/mL (5.50 mM); Clear solution此案可获得 2.25 mg/mL (5.50 mM，饱和度未知) 的澄清溶液。以 1 mL 作液为例，取 100 L 22

4、.5 mg/mL 的澄 DMSO 储备液加到 400 L PEG300 中，混合均匀；向上述体系中加50 L Tween-80，混合均匀；然后继续加 450 L 理盐定容 1 mL。2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.25 mg/mL (5.50 mM); Clear solutionPage 1 of 2 www.MedChemE此案可获得 2.25 mg/mL (5.50 mM，饱和度未知) 的澄清溶液。以 1 mL 作液为例，取 100 L 22.5 mg/mL 的澄 DMSO 储备液加到 900

5、L 20% 的 SBE-CD 理盐溶液中，混合均匀。3. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.25 mg/mL (5.50 mM); Clear solution此案可获得 2.25 mg/mL (5.50 mM，饱和度未知) 的澄 溶液，此案不适于实验周 期在半个以上的实验。以 1 mL 作液为例，取 100 L 22.5 mg/mL 的澄 DMSO 储备液加到 900 L 油中，混合均匀。BIOLOGICAL ACTIVITY物活性 Beclometasone (Beclomethasone)种糖质激素受体 (glucocortico

6、id receptor) 激动剂。IC & Target Glucocorticoid Receptor1体外研究 An inhibition of the normal physiological neutrophil migration and of neutrophil chemotaxis directed by wounding-induced inflammation is detected at 4 h after administration of 25 M Beclomethasone. Tumour cell invasion andmicrometastasis is a

7、lso reduced in embryos incubated in 25 M Beclomethasone 4 h before implantation. In addition,the lysyl oxidase inhibitor -aminoproprionitrile (APN) largely reduces fibrillar collagen and enhances the CHT-TFtransmigration of neutrophils, leading to a significant increase of tumour cell invasion and s

8、ubsequent formation ofmicrometastases. Notably, APN inhibits neutrophil chemotaxis induced by inflammation, indicating that the increaseof tumour cell invasion in APN-treated embryos is correlated with enhanced non-pathological neutrophil migration,but not with inflammation1.PROTOCOLCell Assay 1 The

9、 transgenic lines Tg(fli1:GFP) and Tg(mpx:GFP) are used in this study. 0.2 mM N-phenylthiourea (PTU) is applied toprevent pigment formation from 1 day post-fertilization (dpf). For Pu.1 knockdown, Pu.1 MO (1 mM for partialknockdown and 2 mM for complete knockdown is injected into the yolk at the one

10、-cell stage. For pharmacologicalinhibition, the VEGFR tyrosine kinase inhibitors KRN633 (0.1-1 M) or Sunitinib (0.1-1 M), Beclomethasone (25 M)and -amino-proprionitrile (APN, 500 M) are applied directly to the egg water and refreshed every 2 days. Forpharmacological inhibition, Beclomethasone is app

11、lied to the embryos 4 h before implantation and KRN633, Sunitiniband APN are applied 4-6 h post-implantation. For each cell line or condition, data are representative of threeindependent experiments, with 30 embryos/group. Experiments are discarded when the survival rate of the controlgroup is 90%1.

12、MCE has not independently confirmed the accuracy of these methods. They are for reference only.户使本产品发表的科研献 Pharm Res. 2017 Dec;34(12):2454-2465.See more customer validations on HYPERLINK www.MedChemE www.MedChemEREFERENCESPage 2 of 3 www.MedChemE1. He S, et al. Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model. J Pathol. 2012 Aug;227(4):431-45.McePdfHeightCaution: Product has not